

## Index

- a**
- A1B11 SIRT2-selective inhibitors 233, 235
  - A2B57 SIRT2-selective inhibitors 233, 235
  - acridine 8
  - adenine (A) 25
  - adenosine 88
  - adenosine triphosphate (ATP) 8, 35, 117
  - affinity-guided DMAP (AGD)
    - catalyst-mediated selective chemical protein labeling 309
  - affinity-guided DMAP (4-dimethylaminopyridine) chemistry 309
  - affinity ligand-tethered DMAP catalyst 309
  - [1-<sup>13</sup>C]alanine-NH<sub>2</sub> 282
  - α-amino acid-based HP <sup>13</sup>C chemical probes 293
  - α-hydroxyl acids 95, 101
  - amacrine/horizontal interneurons 78
  - amino acids
    - incorporation of noncanonical 101–103
    - misacylation of non-proteinogenic 94–96
    - misincorporation 87
    - ribosomal translation 103, 104
  - aminoacylation
    - class I ARSs 90
    - ribozyme 94, 95
    - tRNA 90–91, 93, 95
  - aminoacyl dinucleotide 92
  - aminoacyl-transfer RNA (tRNA) 88, 90, 102
  - ARSs 90, 91
  - aminoacyl-pdCpA dinucleotide with 91, 93
    - post-aminoacylation modification 93
    - preparing noncanonical 91
  - aminoacyl-tRNA synthetases (ARSs) 90–91, 96, 354
  - 4-[(2-aminoethyl)carbomoyl]benzyl thioester (ABT) 95
  - 2-amino-4-pentenoic acid 98
  - AMPA receptors
    - chemical labeling and fluorescent visualization 303
    - FRAP analysis 304
  - anti-arrhythmic 43
  - antibody-drug conjugates (ADCs) 253
  - anti-cancer 43
  - anticodon sequence 88
  - anti-malarial agents 43
  - antisense oligonucleotides (ASO) 258–260
  - aquaporin 183
  - 4-armed star-shaped copolymers 209
  - ASO conjugated with tocopherol (Toc-ASO) 261–262
  - Aspidosperma* alkaloids 45, 48, 49, 51, 64
  - assembly lines
    - artificial 68
    - biogenetically inspired synthesis 58–68
    - biomimetic 43, 52

- assembly lines (*contd.*)  
 biosynthetic 45, 48, 58  
 development of 45  
 Macmillan's collective total synthesis  
 45–52  
 nature of 62  
 synthesis of indole alkaloids 52–57  
 atomic force microscope (AFM) 29
- b**
- benzodiazepines 306  
 benzoxadiazole 124  
 $\beta$ -amino acids 87, 95, 335  
 $\beta$ -Cyclodextrin ( $\beta$ -CD) 190  
 bicycle-phage display approach 352  
 biodegradable poly(ether urethane)  
 213  
 biodegradable thermoplastics 207  
 biogenetically inspired synthesis  
 58–68  
 biomimetic cyclization 49  
 bioorthogonal reaction-based  
 glycosylation 136  
 1,4-bis(4-phenylethynyl)benzene (BPEB)  
 units 186, 187  
 block cationomers  
 for gene delivery system 1–18  
 pDNA packaging 2–6  
 rod-shape/toroid-shape 17–18  
 systemic gene therapy 14–16  
 blood cells 8  
 blood circulation  
 of biological compounds 8  
 capability 14  
 capacity 2, 9, 14  
 in longevity 8  
 molecular weight on 115  
 time 115  
 blood flow 73  
 blood vessel  
 endothelial cells 114  
 formation 73  
 BNA/LNA chemistry 260  
 Borromean rings 28  
 bow-tie-shape dendrimers 115, 116  
 brain-derived neurotrophic factor  
 (BDNF) 80
- budding 183  
 bulk degradation 204  
 bump and hole technology 313
- c**
- [1-<sup>13</sup>C] $\alpha$ -amino acid 292, 293  
 [1-<sup>13</sup>C]ascorbate 283–284  
<sup>13</sup>C-benzylformic acid, for H<sub>2</sub>O<sub>2</sub>  
 detection 284  
 [1-<sup>13</sup>C]bicarbonate, for pH sensing  
 283  
 [1-<sup>13</sup>C]dehydroascorbate 284  
 [13C,D3]-*p*-anisidine 284–285  
 cell-based yeast display method 347  
 cell-cycle regulation 75  
 cell-free emulsion based encapsulation  
 method 347  
 cell-free ribosome display method 347  
 cell membranes  
 components of 118  
 negatively-charged 119  
 cell-penetrating peptides (CPP) 10  
 cell-surface AMPA receptors, diffusion  
 dynamics 302  
 cellular uptake  
 efficiency 8, 10, 15  
 process 17  
 rod-length limitation for 14  
 CEST 126  
<sup>13</sup>C-ethylenediaminetetraacetic acid  
 (EDTA) 285–286  
<sup>13</sup>C-ethyleneglycol tetraacetic acid 286  
 C–H activation reaction 224–228  
 chondroitin sulfate (HS) 8  
<sup>13</sup>C hyperpolarized molecular probes  
 aminopeptidase N detection  
 282–283  
 [1-<sup>13</sup>C]ascorbate 283–284  
<sup>13</sup>C-benzylformic acid 284  
 [1-<sup>13</sup>C]bicarbonate 283  
 [1-<sup>13</sup>C]dehydroascorbate 284  
 [<sup>13</sup>C,D]EDTA 285–286  
 [<sup>13</sup>C,D<sub>3</sub>]-*p*-anisidine 284–285  
 [1-<sup>13</sup>C]pyruvate 277–278  
 chemical environment analysis 283  
 enzymatic activity analysis 277

- $\gamma$ -glutamyl transpeptidase 278–281
  - glycolysis and tricarboxylic acid cycle
    - analysis 278
    - scaffold structure 292
  - circular dichroism (CD) spectra 188
  - click chemistry approach
    - HDAC3-selective inhibitor
      - identification 221–224
    - HDAC8-selective inhibitor
      - identification 224
    - SIRT2-selective inhibitors 232–234
  - coordination chemistry-based
    - chemogenetic approach
      - 312–320
  - copper-catalyzed cycloaddition 136
  - Coulomb repulsion 118, 120, 122
  - cyanomethyl ester (CME) 94
  - cyclic peptides 329
  - cyclization, of peptides 349
  - cyclosporin 336, 337
  - cysteine conjugation 133–136
  - cytidine 88
  - cytosine (C) 26
- d**
- D- $\alpha$ -amino acids 95
  - D-amino acid 87, 101, 335
  - degradation behavior of hydrogels 203
  - degree of polymerization (DP) 1, 4
  - degree of protonation 11
  - deoxyribonucleic acids (DNA) 25, 339
    - characteristic of 26
    - design principles 35
    - DNA-PAINT 36
    - immobile DNA junctions 26–28
    - molecular architecture 25–36
    - molecule structure of 25–26
    - nanostructures 25
    - tiles and their assemblies 28–29
    - topologically 28
    - unzipping mechanism 35
  - 2'-deoxyribose ring 25
  - De-SPIO 118
  - D-glucosamine 119
  - Diels–Alder cycloaddition 45
  - diethylenetriamine (DET) 11
  - dissolution dynamic nuclear
    - polarization process 274
  - 1,2-distearoyl-*sn*-glycero-
    - 3-phosphocholine (DSPC) 191
  - disuccinimidyl glutarate crosslinker
    - 352
  - disulfide bond 10
  - DMAP-antibody conjugates 312
  - DMAP-tethered lectins 310
  - DMF 6
  - DNA-based molecular technologies
    - fluorescence blinking control
      - 171–177
    - genetic alphabet expansion
      - 168–171
  - DNA computing 36
  - DNA condensation 1, 5, 18
  - DNA duplex 35
  - DNA forceps 33
  - DNA intercalators 8
  - DNA nanorobot 33
  - DNA nanotechnology 25, 26, 36
  - DNA origami
    - box-shaped 3D 31
    - design 31
    - molecular machines made 33
    - molecular peg board 32–33
    - pinching devices 33–35
    - 2D nanostructures 31
  - DNA packaging 1
  - DNA pliers 33, 35
  - DNA/RNA heteroduplex
    - oligonucleotide (HDO)
      - concept 262–264
      - conjugated with tocopherol
        - (Toc-HDO) 264–268
  - DNA sequence 105
  - DNA strands 26, 28
    - chemical synthesis of 339
  - DNA zipping mechanism 34
  - double-stranded DNA 3
  - doxorubicin 120, 121
  - DREADD technology 313
  - drug delivery system (DDS) 113
  - drug discovery platforms 104–105
  - druggable proteins 330–332

- Ds–Px pair 169  
D-tyrosine 91  
dynamic light scattering (DLS) 2
- e**  
eight-armed PEG 209  
elastic pressure 204  
emitting fluorescent dye 36  
endosomal escape 15  
endosome escape 11–12  
endothelial cells  
  growth 72  
  survival of 73  
  VEGFRs 73  
enhanced permeable retention (EPR)  
  effect 114, 117, 118, 123, 124,  
  129  
enzymatic activity, <sup>13</sup>C molecular probes  
  277  
enzymatic glycosylation 136–137  
epidermal growth factor receptor  
  (EGFR) 9  
epigenetics 219–221  
ethylene diamine (EDA) 11  
extracellular matrix (ECM) 74, 78, 118,  
  119
- f**  
flavin adenine dinucleotide (FAD) 239  
flexizymes 355–356  
Flory–Rehner model 204  
fluorescence 139, 147, 152  
fluorescence-activated cell sorting  
  (FACS) device 33  
fluorescence blinking  
  blinking kinetics 172  
  isomerization blinking 176  
  redox blinking 175  
  single molecule detection 171  
  triplet blinking 174  
fluorescence correlation spectroscopy  
  (FCS) 172  
fluorescence recovery after  
  photobleaching (FRAP) method  
  302  
fluorescent biosensors 305  
fluorescent imaging plate reader  
  (FLIPR™) 304  
fluorescent labeling, of GABA<sub>A</sub> receptor  
  306  
fluorescent nanogel thermometer (FNT)  
  124  
fluorescent polymeric thermometer  
  (FPT) 124, 125  
fluorescent Zn<sup>II</sup> chemosensors 314  
2-fluorodeoxy-D-glucose (2FDG) 117  
formylmethionine (fMet) 89  
four-base codon method 98, 100  
fucose-glycoconjugates 138  
functional peptides  
  cell-based yeast display 347  
  cell-free emulsion based  
  encapsulation methods 347  
  cell-free ribosome display 347  
  DNA sequencing techniques 346  
  intracellular peptide selection  
  340–341  
  mRNA-display method 345–347  
  natural peptide synthesis 339–340  
  phage display method 341–345  
  ribosomal synthesis 337–339
- g**  
GABA<sub>A</sub> receptors 306, 307  
galactose-modified proteins 137  
gamma-aminobutyric acid (GABA)  
  306  
γ-amino acids 95  
γ-glutamyl-[1-<sup>13</sup>C]glycine  
  (γ-Glu-[1-<sup>13</sup>C]Gly) 278–279,  
  281  
γ-glutamyl transpeptidase (GGT)  
  analysis 278–281  
GB-GC-SPIO 118  
GC-SPIO 117, 119  
gene delivery  
  impact for 6  
  nuclease attack 6  
  polyplex micelles 6–14  
gene silencing  
  after ASO or Toc-HDO injection  
  265  
  Toc-ASO 262

- gene therapy 14–16
- genetic alphabet expansion
- high-affinity DNA aptamer generation 169
  - nucleotide modifications 168
  - unnatural base-pair 168
- genetic code
- decoding 88–90
  - expansion 352
  - flexizymes 355–356
  - in vitro* chemical ligation approach 353
  - limitation 354
  - messenger RNA (mRNA) 88, 90
  - non-standard base method 101
  - RaPID system 356–361
  - reprogramming 97–98
- glomerular cells 115, 116
- glycan molecule technology 132
- bioorthogonal reaction-based glycosylation 136
  - cysteine conjugation 133–136
  - enzymatic glycosylation 136–137
  - in vivo* organ selective Au-catalyzed reactivity 153
  - on live cells 148–150
  - lysine conjugation 133
  - as metal carriers 151
- glycans 132
- natural 155
  - protein-conjugation 133
- glycol chitosan (GC) 117
- glycolide 207
- glycolysis 117
- glycoprotein labeling, with DMAP-tethered lectin 311
- glycosaminoglycans (GAGs) 8–10
- gold nanoparticles 32
- gold nanorods 32
- G-quadruplex formation 35
- green fluorescent protein-fusion technology 298
- guanine (G) 25
- guanosine 88
- h**
- HDAC3-selective inhibitors 221–224
- HDAC6-insensitive inhibitors 224–228
- HDAC8-selective inhibitors 224
- HDO Conjugated with Tocopherol (Toc-HDO)
- adverse effect 266–268
  - on ApoB mRNA levels 265
  - construction 264
  - design 264
  - mechanism 268
  - potency 264–266
- Heck cyclization 49
- Henderson–Hasselbalch equation 283
- heparan sulfate (HS) 8
- hexaethylene glycol chains 127
- hexammine cobalt 17
- histone
- acetylation and methylation 219, 220
  - chemical modification 220
- histone deacetylase (HDAC) inhibitors 221
- HDAC3-selective inhibitors 221–224
  - HDAC6-insensitive inhibitors 224–228
  - HDAC6-selective inhibitors 228, 229
  - HDAC8-selective inhibitors 224, 225
  - SIRT1-selective inhibitors 228–232
  - SIRT2-selective inhibitors 232–234
- histone lysine demethylase (KDM) inhibitors
- KDM4C inhibitors 235–237
  - KDM5A inhibitor identification 237–238
  - KDM7B inhibitor identification 238–239
  - LSD1 inhibitor identification 239–250
- Holliday Junction 28, 33
- H-thymidine labeling technique 77

- hydrazine-based LSD1-selective inhibitors 250
- hydrogels  
 degradation behavior 203–205  
 nondegradable 204
- hydrophilic block 3, 7
- hyperpolarization 273–275
- hyperpolarized (HP) molecular imaging probe  
 of chemical environment 283–286  
 design strategy 287–294  
 of enzymatic activity 277–283  
 HP <sup>15</sup>N molecular probes 286–287  
 requirements 275–227
- i**
- immobile DNA junctions 26–28
- indole alkaloids  
*Aspidosperma* families of 52  
 biogenetically inspired synthesis 58, 68  
 biosynthetic precursors 44  
 monoterpene 43  
 synthesis of terpenoid 43  
 systematic synthesis of 52–57
- injured brain regeneration  
 angiogenesis biology 71–73  
 of cell cycle 75–76  
 molecular technology to promote angiogenesis 74–75  
 neurogenesis 77–78  
 neuron regeneration 78–80  
 potential of 71
- integrated oxidation/reduction/cyclization (iORC) 52, 54–57
- integrin 183
- intracellular peptide selection 340–341
- intravenous (IV) injection 2
- intravital real-time CLSM (IVRTCLSM) 9
- in vitro* bioconjugation methods 298
- in vivo* metal-catalyzed reactions 150–153
- in vivo* kinetics  
 of monosaccharide-modified proteins 137–139  
 of oligosaccharide-modified proteins 139–150
- in vivo* translation steps 338
- ion channel type glutamate receptor (iGluR) 314
- ion transportation 183
- isoleucyl-tRNA synthetase (IleRS) 91
- isomerization blinking 176
- isothermal titration calorimetry (ITC) 198
- isothiocyanate method 133
- isozyme-selective histone deacetylase (HDAC) inhibitors 221–234
- j**
- Jeffery–Heck cyclization 48, 49
- k**
- KDM4C inhibitors 235
- KDM5A inhibitors 237–238
- KDM7B inhibitors 238–239
- Kopsia* alkaloids 45, 48–50
- l**
- L- $\alpha$ -amino acids 95
- ligand-directed alkyloxyacyl imidazole (LDAI) chemistry 302
- ligand-directed chemistry, for neurotransmitter receptor proteins  
 affinity-based chemical approaches 301  
 AMPA receptors 302  
 chemical labeling coupled with BFQR system 305  
 enzyme-/peptide-tagged approaches 301  
 fluorescent biosensors 302  
 fluorescent protein utilization 300  
 GABA<sub>A</sub> receptors 306  
 SEP-tagged AMPA receptors 302  
 synthetic fluorophore 304
- ligand-directed dibromophenyl benzoate (LDBB) chemistry 302
- ligand-directed tosylate (LDT) chemistry 301

- ligand-gated ion transportation 187  
 linear polymer 119  
 Lipinski's rules 330, 332  
 live-cell surface protein analysis, AGD  
   reaction for 308–312  
 lower critical solution temperature  
 (LCST) 7, 125, 127  
 lysine-specific demethylase 1 (LSD1)  
   234  
   catalytic mechanism 239  
   hydrazine-based 250, 251  
   inactivation mechanism 250  
   NCL1 and NCL2 242  
   PCPA-Lys-4 H3-21 245  
   PCPA-lysine analogue hybrid  
     compounds 242  
   phenylcyclopropylamine 242  
   protein-targeted drug delivery 245  
   small-molecule-based drug delivery  
     system 250–253  
   target-guided synthesis 239–250
- m**  
 Macmillan's collective total synthesis  
   45–52  
 macrocyclic multiblock amphiphile  
   190  
 macrocyclization 334  
 macropinocytosis 10  
 magnetic resonance imaging (MRI)  
   118, 273  
 mannose-bearing proteins 138  
 matrix metalloproteinase (MMP) 10  
 membrane functionalization  
   with biological molecules 184  
   genetic engineering 198  
   ligand-gated ion transportation 187  
   light-triggered membrane budding  
     190  
   multipass transmembrane structure  
     formation 185  
   nanobiodevice development 193  
   semi-biological approach 191  
   single molecule force spectroscopy  
     192  
   supramolecular ion channel  
     formation 187  
   synthetic approach 185  
   transmembrane structure analysis  
     192  
 membrane permeability 336–337  
 messenger RNA (mRNA) 13, 87, 338  
   aminoacyl-transfer RNA (tRNA) 88  
   display method  
     advantage 346  
     origins of 345, 346  
   genetic code 88–90  
**micelle-Dox** nanoparticles 118  
 microRNA (miRNA) 35  
 Mizoroki–Heck reaction 49  
 molecular analysis 273  
 molecular crowding environment 298  
 monosaccharide-modified proteins  
   dissection-based kinetic and  
     biodistribution studies 137  
   noninvasive imaging 138  
 monoterpene indole alkaloid 43  
 mPEG-PTMC 208  
 Müller glial cells 78  
 multipass transmembrane (MTM)  
   structure formation 185
- n**  
*N*-acetyl galactosamine (GalNAc) 261  
*N*Ac-neuraminic acid 139  
*N*-acyl- $\alpha$ -amino acids 95  
*N*-alkyl- $\alpha$ -amino acids 101  
*N*-alkyl-amino acids 95  
 nanoarrays 32  
 nanobiodevice development 193  
 nanofibers 79  
 nanoparticles 10, 80, 114  
 nanoscale 29  
 nanotechnology 80  
 natural peptide synthesis 333,  
   339–340  
 natural proteins 298  
 NCC149 identification 224  
 NCD38 250  
 NCDM-32 237  
 NCH-31 226  
 [<sup>15</sup>N]choline 286  
 NCO-90 232, 234  
 [<sup>15</sup>N,<sup>2</sup>D<sub>9</sub>]TMPA 291–292

- [<sup>15</sup>N,<sup>13</sup>C]<sub>6</sub>trimethylglutamine 286  
 [<sup>15</sup>N,<sup>13</sup>C]<sub>6</sub>trimethylphenylammonium  
 ([<sup>15</sup>N,<sup>13</sup>C]<sub>6</sub>TPMA) 288–291  
 neurobiology 77  
 neuroblasts 74  
 neurodegeneration 80  
 neurogenesis 77–78  
 neuronal progenitor cells 74  
 neuropathology 77  
 neurotrophin-3 80  
*N*-glycoalbumins 145–148  
<sup>15</sup>N hyperpolarized molecular probes  
 286  
*N*-isopropyl acrylamide block methyl  
 methacrylate  
 (NIPAAm-*b*-MMA) 125  
*N*-methyl- $\alpha$ -amino acids 101  
*N*-methyl-amino acid 101  
*N*-methylation 335–336  
 [<sup>15</sup>N]-*o*-aminophenol-*N,N,O*-triacetic  
 acid (APTRA) 287  
 non-proteinogenic amino acids (nPAAs)  
 87, 96, 97, 101, 329  
 non-sense codon method 97, 98  
 non-standard base method 100  
 normal (healthy) cells  
 morphology and temperature 124  
 oxidative phosphorylation 117  
 produce ATP 117  
 tissue applications 124  
 vs. tumor cells 114, 125  
*N*-oxalylglycine (NOG) 236  
 [<sup>15</sup>N]pyridine 286  
 nuclear magnetic resonance (NMR)  
 273  
 cyclosporin 336–337  
 nuclear spin detection 274  
 sensitivity 273  
 nuclear pore complex (NPC) 13  
 nucleic acid delivery system 8  
 nucleobases 25  
 nucleotides 88
- O**  
 oligodeoxynucleotide (ODN) 123  
 oligonucleotide (ODN) 123
- On-cell Coordination Chemistry  
 (OcCC)  
 in cultured neuron system 320  
 ion channel type glutamate receptor  
 314  
 ionotropic glutamate receptors 319  
 metabotropic glutamate receptors  
 316, 319  
 Pd(bpy)-mediated allosteric  
 activation 320  
 primary cultured neuronal system  
 317  
 schematic illustration 318  
 optochemical genetics 314  
 organocascade catalysis 45–52  
 organocatalyst-based protein labeling  
 method 309  
 organocatalytic synthesis 47  
 osmotic pressure 204  
 oxidative phosphorylation 117
- P**  
 palladium-catalyzed decarboxylative  
 coupling 52  
 paramagnetic chemical exchange  
 saturation transfer (PARACEST)  
 125  
 paranemic crossover (PX) 29  
 PCPA-drug conjugates (PDCs) 252,  
 253  
 PCPA-tamoxifen conjugates 252, 253  
 Pd(bpy)-mediated allosteric activation,  
 of glutamate receptors 320  
 PEG<sub>10k</sub>-*b*-polyphosphoramidate (PPA)  
 6  
 PEG-*b*-poly{N'-[N-(2-aminoethyl)-  
 2-aminoethyl]aspartamide}  
 {PEG-*b*-P[Asp(DET)]} 7  
 PEGylation 8, 9  
 PEI 11, 12, 14, 15  
 pentameric ligand-gated ion channel  
 185  
 peptide amide backbone modifications  
 335  
 peptide-amphiphile 79  
 peptide nucleic acids (PNA) 35



- peptidyl-tRNA 103, 104
- phage display method 341–345
- pharmacokinetics  
 of bow-tie-shape dendrimers 115  
 of particles 114
- phenylboronic acids (PBA) 8
- phenylcyclopropylamine (PCPA) 242
- phosphodiester linkage 25
- phosphorothioate bond (PS) linkage 259
- photochemical internalization (PCI) 12
- photoirradiation 15
- phthalocyanine-loaded dendrimers (DPc) 12
- plasma membrane 183
- plasmid DNA (pDNA)  
 bioavailability of 1  
 packaging  
 by block cationomers 2–6  
 globule-shape 5  
 into polyplex micelles 1  
 rod-shape/globule-shape 3–6  
 spooling of 17
- p*-methoxy benzyl (PMB) 49
- point accumulation for imaging in  
 nanoscale topography (PAINT) 36
- poly( $\beta$ -benzyl-L-aspartate) (PBLA) 11
- polyester synthesis 97
- poly(ethylene glycol) (PEG) 2, 10, 118, 206
- polyethylene glycol (PEG)-ylated polyester 115
- polyethylene oxide chains 116
- poly(2-ethyl-2-oxazoline) 7
- polyion exchange reaction 6
- polylactide (PLA)  
 copolymer 205  
 stereocomplex (SC) 205
- polymer binding 16
- poly-methyl methacrylate (PMMA) 125
- poly(*N*-isopropylacrylamide)-*b*-P(Asp(DET)) (PNIPAM-*b*-P(Asp(DET))) 7
- poly-*N*-*n*-propylacrylamide (PNNPAM) 124
- poly-(2-*n*-propyl-2-oxazoline) (PnPrOx) 7
- polypeptides 87
- polyplex micelles  
 bioavailability of 8  
 disintegration of 8  
 for efficient cellular entry 9–10  
 for efficient transcription 13–14  
 mechanism of 2  
 for nuclear translocation 13  
 pDNA stable encapsulation of 6–9  
 of PEG<sub>10k</sub>-*b*-polyphosphoramidate (PPA) 6  
 for safe endosome escape 11–12  
 systemic gene delivery system 6–14
- polyurethane 211
- positive allosteric modulator 316
- positron emission tomography (PET) 117
- prestin  
 application to biological device 194  
 isothermal titration calorimetry 198  
 mRNA expression 192  
 mutants 199  
 prolyl-tRNA synthetase (ProRS) 91  
 purification 197  
 reconstitution into lipid bilayer 196  
 structural analysis 194  
 transmembrane structure 192  
 Western blotting 197
- protein 297  
 adsorption 9  
 immobilization 298
- protein-based semisynthetic biosensors 304
- proteinogenic amino acids (PAAs) 87, 95, 97
- protein-targeted drug delivery 245
- proton-sponge effect 11
- pseudo-natural peptide synthesis  
 amino acid replacement 354–355  
 genetic code expansion 352–354  
 genetic code reprogramming 355–361

- pseudo-natural peptide synthesis  
(*contd.*)
- intein cyclization 348–351
  - post-translational modification  
351–352
  - SICLOPPS 348–351
  - SPPS limitations of 348
- PTMC-PEG-PTMC triblock  
copolymers 208
- PURE translation system 354
- puromycin 345
- r**
- radical nanoparticles (RNP) 120
- Random non-standard Peptides  
Integrated Discovery (RaPID)  
105, 356–361
- reactive oxygen species (ROS) 12
- redox blinking 175
- redox status 283
- retinal progenitors 78
- reverse two-hybrid method, in *E. coli*  
340
- rhodopsin 185
- ribosomal RNA (rRNA) 338
- ribosomal synthesis, of peptides 337
- ribosomal translation
- amino acids 103–104
  - aminoacyl-tRNA synthetases 90–91
  - assigning non-proteinogenic amino  
acids 95–101
  - drug discovery platforms 104–105
  - genetic code decoding 88–90
  - improvement of substrate tolerance  
103–104
  - noncanonical aminoacyl-tRNAs  
91–95
  - substrate scope 101–103
- RIKEN click reaction 142
- RNP-TEMDO-UBD 120, 122
- RNP-TEMDO-UBD-DA 122
- rod/cone photoreceptor cells 78
- s**
- scaffold structure
- <sup>13</sup>C hyperpolarized molecular probes  
292
  - <sup>15</sup>N HP probes 288
- semisynthetic antibody-DMAP  
conjugates 310
- semisynthetic biosensor construction  
305
- semisynthetic fluorescent biosensors  
307
- serum proteins 8
- shear stress 9
- short interfering RNA (siRNA)  
257–258
- single molecule force spectroscopy  
(SMFS) 192
- single-stranded DNA 28
- siRNA conjugated with tocopherol  
(Toc-siRNA) 261
- small angle X-ray scattering (SAXS) 31
- small-molecule-based drug delivery  
system 250–253
- SNAP-tag based indicator proteins  
305
- solid phase synthesis of peptides (SPPS)  
348
- spermidine 17
- spirocyclization reaction 174
- stereocomplex (SC) of polylactide 205
- stroke 73, 74, 80
- structure-based drug design
- KDM4C inhibitor identification 235
  - KDM5A inhibitor identification 237
  - KDM7B inhibitor identification 238
  - SIRT2-selective inhibitors 232–234
- Strychnos* alkaloids 45, 48
- substrate-based drug design, for  
HDAC6-selective inhibitor  
identification 228
- subventricular zone (SVZ) 74
- 3-sulfopropyl (SPA) 124
- super-paramagnetic iron oxide (SPIO)  
117
- super-resolution fluorescent microscopy  
36
- supramolecular ion channel formation  
187
- surface degradation 203
- systematic evolution of ligands by  
exponential enrichment (SELEX)  
165, 167, 170

**t**

target-guided synthesis (TGS)  
  LSD1 inhibitor identification  
    239–250  
  for SIRT1-selective inhibitor  
    identification 228–232  
TEMDO-UBD 120, 122  
TEMDO-UBD-DA 122  
TEMPO 122, 123  
tetraethylenepentamine 11  
therapeutic antibodies 332  
therapeutic oligonucleotides  
  ASO 258–259, 261–262  
  chemical modifications 259–260  
  delivery ligand-molecule 261  
  DNA/RNA heteroduplex  
    oligonucleotide 262–268  
  internucleotide linkage modifications  
    259–260  
  ligand-conjugation for drug delivery  
    systems 261  
  schematic illustration 263  
  siRNA 257–258, 261  
  sugar moiety modification 260  
  vitamin E 261  
thermoresponsive block 7  
thymine (T) 25  
tissue degeneration 117  
tissue regeneration  
  cell scaffolding for 74  
  VEGF-conjugated biomaterials  
    74  
total internal reflection fluorescence  
  (TIRF) microscope 36  
*trans-cis* photo-isomerization  
  176  
transfer RNA (tRNA) 338  
triblock copolymers 7  
triethylenetetramine (TET) 11  
triplet blinking 174  
tumor angiogenic factor (TAF) 72

## tumor cells

  aberrant morphology and size  
    114–117  
  aberrant pH microenvironment  
    117–124  
  glucose for energy production 124  
  growth 113  
  microenvironment temperature of  
    124–129  
  VEGF 73  
tumor growth 72

**u**

[U-<sup>13</sup>C,U-D]glucose 278  
undruggable proteins 332–333  
unnatural amino acids 335  
urea benzene derivatives (UBD) 127  
uridine 88  
UV light-triggered membrane budding  
  190

**v**

vascular endothelial cells 8  
vascular endothelial growth factor  
  (VEGF) 72, 73  
vascular permeability factor (VPF) 72  
VEGF-sponge 75  
visible light-triggered membrane  
  budding 190  
vitamin E 261

**w**

Warburg effect 117, 118, 124, 129  
Watson–Crick base pairs 89  
whole-cell patch-clamp recording 199  
Wieland–Gumlich aldehyde 48

**z**

Z-DNA 28  
zeta-potential 2, 9, 10  
zipping mechanism 35

